Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Pasquale Bove
Trastuzumab Emtansine Is the Standard Second-Line Treatment Following Horizontal Blockade in First Line of Advanced HER-2 Positive Breast Cancer: A Plant That Has Still to Grow
Integrative Cancer Science and Therapeutics
Related publications
Novel Approaches to Target HER2-positive Breast Cancer: Trastuzumab Emtansine
Cancer Management and Research
Oncology
Safety and Efficacy of Trastuzumab Emtansine in Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: A Meta-Analysis
Scientific Reports
Multidisciplinary
Clinical Experience of Dual Targeted Blockade (Pertuzumab + Trastuzumab + Docetaxel) in Neoadjuvant Therapy of Early HER-2-Positive Breast Cancer
Effective Pharmacotherapy
Mechanisms of Acquired Resistance to Trastuzumab Emtansine in Breast Cancer Cells
Molecular Cancer Therapeutics
Cancer Research
Oncology
Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab With Taxane for Human Epidermal Growth Factor Receptor 2–positive Advanced Breast Cancer: Final Results From MARIANNE
Cancer
Cancer Research
Oncology
An Open-Label Safety Study of Lapatinib Plus Trastuzumab Plus Paclitaxel in First-Line HER2-Positive Metastatic Breast Cancer
Oncologist
Cancer Research
Medicine
Oncology
Pcn75 - Budget Impact Model of Subcutaneous Trastuzumab Compared With Intravenous Trastuzumab on the Treatment of Her-2 Positive Breast Cancer in the Brazilian Private Healthcare System
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Relationship Between Tumor Biomarkers and Efficacy in MARIANNE, a Phase III Study of Trastuzumab Emtansine ± Pertuzumab Versus Trastuzumab Plus Taxane in HER2-positive Advanced Breast Cancer
BMC Cancer
Cancer Research
Oncology
Genetics
Second-Line Treatment of Advanced Gastric Cancer: Where Do We Stand?
Journal of the National Comprehensive Cancer Network : JNCCN
Medicine
Oncology
